Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and the maximum tolerated dose of
GRN163L administration in treating patients with refractory or relapsed solid tumor
malignancies.